Shire readies Gaucher drug Vpriv
February 23, 2010Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv
Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …
Lilly UK appoints Ramona Sequeira managing director
February 23, 2010Research and Development, Sales and Marketing appointment, lilly, research and development, sales and marketing
Lilly UK has appointed Ramona Sequeira managing director, UK and Republic of Ireland.She replaces Andrew Hotchkiss who becomes vice president …
Low Adderall sales hit Shire
February 22, 2010Sales and Marketing 2009 financials, Adderall, Shire
Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR. Product sales were down …
Novartis gains edge in MS treatment race
February 22, 2010Research and Development, Sales and Marketing Cladribine, Gilenia, MS, Novartis
Novartis’ new oral multiple sclerosis treatment Gilenia will be given a priority review by the FDA.This could lead to a …
Sanofi’s Humenza poised to be Europe’s fifth swine flu vaccine
February 22, 2010Sales and Marketing Sanofi Pasteur, Tyverb, Zeftera, swine flu
Sanofi Pasteur’s Humenza is set to become the fifth swine flu vaccine in Europe after gaining the support of a …
Taro will close Irish facility next month
February 22, 2010Manufacturing and Production Sun Pharma, Taro Pharma, manufacturing and production
Israeli drugmaker Taro Pharma has decided to halt manufacturing at a plant in Tipperary, Ireland, resulting in the loss of …
RTS Life Science Appoints Richard Carpenter
February 22, 2010Manufacturing and Production appointment, manufacturing and production, rts life science
RTS Life Science has expanded its US field-based sales team, appointing Richard Carpenter Mid-Atlantic sales manager. The company, which supplies …
ReNeuron to begin landmark stem cell trial for stroke
February 19, 2010Research and Development ReNeuron, stem cell
ReNeuron has been given the go-ahead to begin clinical trials of the first ever stem cell therapy for patients disabled …
UK contractor Excelsyn sold to AMRI
February 19, 2010Manufacturing and Production AMRI, Excelsyn
UK contract development and manufacturing services company Excelsyn has been bought for $19 million by US rival AMRI, which said …
Pharma manufacturing news in brief
February 19, 2010Manufacturing and Production AMPAC Fine Chemicals, Avrio, Haupt Pharma, NeoStem
German contract manufacturing organisation (CMO) Haupt Pharma said its site in Latina, Italy, has passed an FDA inspection. Following the …
77 million Europeans fuelling counterfeits market
February 19, 2010Sales and Marketing Europe, Pfizer, counterfeits
A new survey commissioned by Pfizer shows that Europeans are fuelling a counterfeit medicines market worth €10.5 billion.The findings are …
Tracleer continues to fuel Actelion growth
February 19, 2010Sales and Marketing Actelion, Tracleer
Actelion has posted a 20% increase in revenue on the strength of its pulmonary hypertension treatment Tracleer. The drug saw …
Rituxan gains approval for most common leukaemia
February 19, 2010Sales and Marketing FDA, MabThera, Rituxan, blood cancer
Roche’s blockbuster cancer treatment MabThera/Rituxan has been approved by the FDA for the treatment of adult leukaemia. The drug earned …
Clinipace appoints Bud Owen and Daryl Porter
February 19, 2010Research and Development Clinipace, appointment, research and development
CRO and eClinical technology specialist Clinipace Worldwide has appointed Bud Owen as its chief financial officer, while Daryl Porter has …
Dr Jay Feingold joins Daiichi Sankyo
February 19, 2010Research and Development Daiichi Sankyo, appointment, research and development
Daiichi Sankyo’s US arm has appointed Dr Jay Feingold vice president of medical affairs. In this role his will manage …
Plans for more home care on NHS could save billions
February 18, 2010NHS, home care
The NHS is to provide more dialysis and chemotherapy at home as part of a government bid to move treatment …
Québec supports $38m Galderma investment
February 18, 2010Manufacturing and Production Canada, Galderma, Quebec, biopharmaceutical
The regional government in Québec in Canada is to contribute 10% of the costs of a new investment in manufacturing …
Merck’s HIV treatment fails in phase III
February 18, 2010Research and Development HIV, Merck
Merck’s HIV treatment vicriviroc has disappointed in phase III trials, and may be dropped by the company. The results failed …
Hospital criticised for profiting from medicines trade
February 18, 2010Manufacturing and Production parallel trade, supply chain
An NHS hospital has been heavily criticised for trading in medicines to make a profit. It has emerged that the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
